2 not yet recruiting, 1 recruiting. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Not yet recruiting 2, Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Fallopian Tube Cancers: new trials by email Literature Review of Fallopian Tube Cancers trials Research Report on Fallopian Tube Cancers
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer (ArginaidĀ®) Oral Arginine, (R-GeneĀ® 10) IV Arginine, Pembrolizumab - Platinum Resistant Ovarian Cancer, Fallopian Tube Cancers | Phase 1 | Not yet recruiting | Rebecca Arend | 24 | 2026-09-01 | 2026-10-15 |
| IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer Sacituzumab govitecan monotherapy - Epithelial Ovarian Cancer, Fallopian Tube Cancers | Phase 1 | Not yet recruiting | Shanghai Gynecologic Oncology Group | 19 | 2026-07-01 | 2026-06-30 |
| CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer TORL-1-23 and paclitaxel, TORL-1-23 and carboplatin, TORL-1-23, paclitaxel, and carboplatin - FIGO Stage III and IV Ovarian Cancer, Fallopian Tube Cancers | Phase 1 / Phase 2 | Recruiting | TORL Biotherapeutics, LLC | 60 | 2025-12-10 | 2026-07-13 |
Fallopian Tube Neoplasms (3) · Carcinoma, Ovarian Epithelial (1) · Ovarian Neoplasms (1)
Adnexal Diseases (3) · Fallopian Tube Diseases (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Genital Diseases (3) · Genital Diseases, Female (3) · Genital Neoplasms, Female (3) · Neoplasms (3) · Neoplasms by Site (3) · Urogenital Diseases (3) · Urogenital Neoplasms (3) · Carcinoma (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Gonadal Disorders (1)
Paclitaxel (2) · Arginine (1) · Bevacizumab (1) · Carboplatin (1) · Cyclophosphamide (1) · Dimethoate (1) · pembrolizumab (1)
Rebecca Arend (1) · Shanghai Gynecologic Oncology Group (1) · TORL Biotherapeutics, LLC (1)
United States (2) · China (1)